BUZZ-因杰富瑞将 Inspire Medical Systems 的评级下调至 "持有",该公司股价下跌

路透中文
Oct 24
BUZZ-因<a href="https://laohu8.com/S/JEF">杰富瑞</a>将 <a href="https://laohu8.com/S/INSP">Inspire Medical Systems</a> 的评级下调至 "持有",该公司股价下跌

10月24日 -

** 医疗技术公司Inspire Medical Systems INSP.N股价盘前下跌近3%至77.9美元

** 杰富瑞将该公司的股票评级从 "买入 "下调至 "持有

* 杰富瑞将该公司的股票评级从 "买入 "下调至 "持有",理由是对该公司加速销售增长以实现中期目标的能力信心下降,并且不再期望通过倍数扩张来提高估值。

** 券商还将该股的目标价从 160 美元下调至 85 美元,较上一交易日收盘价上涨 6%。

** 杰富瑞(Jefferies)表示,GLP-1 减肥药带来的持续不利因素、竞争加剧和市场份额下降、医生报销疲软,以及对 Inspire 5(公司下一代睡眠呼吸暂停设备) 的预期有限,都可能阻碍该公司 2026 年的销售加速增长。

** 20 位分析师的平均评级为 "买入";PT 中值为 125 美元--数据由 LSEG 编制

** 截至上一交易日收盘,该公司股价年累计下跌近57

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10